Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

255.80
-2.6500-1.03%
Volume:2.55M
Turnover:646.80M
Market Cap:616.30B
PE:29.62
High:257.80
Open:256.22
Low:251.95
Close:258.45
52wk High:281.07
52wk Low:184.66
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.57
T/O Rate:0.11%
Dividend:5.24
Dividend Rate:2.05%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.25
PE(LYR):23.18

Loading ...

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Alert on EOG CFO Appointment Incorrectly Tagged to J&J Withdrawn

Reuters
·
Sep 24

EOG Resources Announces Ann Janssen's Retirement and Jeff Hibbard as Next CFO

THOMSON REUTERS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23

New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 23

J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population

THOMSON REUTERS
·
Sep 23

Kimberly-Clark Offers Remedies in Bid for EU Approval of Kenvue Deal

Reuters
·
Sep 23

Medtronic PLC Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 23

Johnson & Johnson's Caplyta Has More Than $5 Billion Peak Sales Potential, UBS Says

MT Newswires Live
·
Sep 23

Dow Falls 134 Points on Losses for Shares of Cisco, JPMorgan Chase

Dow Jones
·
Sep 22

DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026

Reuters
·
Sep 22

J&J DePuy Synthes to Showcase Next-Generation Trauma Devices at Orthopaedic Trauma Association Annual Meeting

Reuters
·
Sep 22

Michael Yee Reiterates Buy on JNJ, Maintains $320 Price Target on Caplyta’s Strong Bipolar Mania Prospects

TIPRANKS
·
Sep 22

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22